ResMed (NYSE: RMD) CEO sells 8,009 shares under Rule 10b5-1 plan

Rhea-AI Filing Summary

ResMed Inc. Chief Executive Officer Michael J. Farrell exercised options for 8,009 shares of ResMed common stock at $101.64 per share on October 7, 2025, then sold 8,009 shares at a weighted average price of $282.8483 in multiple trades between $280.95 and $283.90 under a Rule 10b5-1 plan adopted October 31, 2024.

After these transactions, he directly held 467,792 ResMed shares, and an additional 2,090 shares were held indirectly through the Lisette and Michael Farrell Family Trust. The options first became exercisable on November 11, 2019 and were scheduled to expire on November 14, 2025, vesting one-third per year.

Insights

Corporate Governance Analyst

Insider used an established Rule 10b5-1 plan to exercise options and sell shares.

The transactions show an officer exercising 8,009 options at $101.64 and selling the same number of shares at a weighted average of $282.85, consistent with a pre‑arranged trading plan adopted 10/31/2024. This pattern reduces direct beneficial ownership from 475,801 to 467,792.

The primary dependence is the 10b5-1 plan timing and option vesting/expiration (options expire 11/14/2025). Watch for any further scheduled exercises or plan disclosures near option expiration over the next few months.

Compensation & Equity Specialist

Option exercise and immediate sale are execution of equity compensation, not an intra-day trading signal.

The exercised options had an exercise price of $101.64 and zero reported cash price for derivative conversion, implying standard option settlement and immediate disposition of the resulting shares. Vesting began 11/11/2019 with a three-year tranche schedule (1/3 per year).

Given the option expiration on 11/14/2025, monitor equity plan activity and future Form 4s for additional exercises as expiration approaches.

Insider Trade Summary

Exercise and Sale: 8,009 shares ($1.45M approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Farrell Michael J.

Role Chief Executive Officer

Sold 8,009 shs ($2.27M)

Approx. gross sale proceeds $2.27M

Approx. exercise cost $814K

Approx. pre-tax spread $1.45M

Type	Security	Shares	Price	Value
Exercise	ResMed Common Stock Options	8,009	$0.00	$0.00
Exercise	ResMed Common Stock	8,009	$101.64	$814K
Sale	ResMed Common Stock	8,009	$282.8483	$2.27M
holding	ResMed Common Stock	--	--	--

Holdings After Transaction: ResMed Common Stock Options — 8,011 shares (Direct); ResMed Common Stock — 467,792 shares (Direct); ResMed Common Stock — 2,090 shares (Indirect, Lisette and Michael Farrell Family Trust)

Footnotes (3)

1. F1. The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
2. F2. This transaction was executed in multiple trades at prices ranging from $280.95 - $283.90. The price reported above reflects the weighted average sale price.
3. F3. Represents date options first become exercisable. Options vest 1/3 per year.

Key Figures

Shares sold: 8,009 shares Weighted average sale price: $282.8483 per share Option exercise price: $101.64 per share +4 more

7 metrics

Shares sold 8,009 shares ResMed common stock sold on October 7, 2025

Weighted average sale price $282.8483 per share Multiple trades between $280.95 and $283.90

Option exercise price $101.64 per share ResMed stock options exercised for 8,009 shares

Direct holdings after transaction 467,792 shares ResMed common stock held directly by Michael J. Farrell

Indirect holdings after transaction 2,090 shares ResMed stock held via Lisette and Michael Farrell Family Trust

Option expiration date 2025-11-14 Expiration date of exercised stock options

Rule 10b5-1 plan adoption date October 31, 2024 Trading plan governing the reported sale

Key Terms

Rule 10b5-1 plan, weighted average sale price, derivative security, ResMed Common Stock Options

4 terms

Rule 10b5-1 plan regulatory

"A Rule 10b5-1 plan adopted October 31, 2024 governed the transaction"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average sale price financial

"The price reported reflects the weighted average sale price"

derivative security financial

"Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

ResMed Common Stock Options financial

"Security title listed as ResMed Common Stock Options"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 10/09/2025 - 11:03 AM Learn about SEC filing dates

FAQ

What insider transaction did ResMed (RMD) report for Michael J. Farrell?

Michael J. Farrell exercised options for 8,009 ResMed shares at $101.64 per share and sold 8,009 shares at a weighted average price of $282.8483 on October 7, 2025, under a Rule 10b5-1 trading plan.

How many ResMed (RMD) shares does Michael J. Farrell hold after this Form 4?

After the reported transactions, Michael J. Farrell directly held 467,792 ResMed common shares and indirectly held 2,090 additional shares through the Lisette and Michael Farrell Family Trust, according to the reported post-transaction holdings.

What prices were involved in Michael J. Farrell’s ResMed (RMD) stock sale?

Farrell’s sale covered 8,009 shares at a weighted average price of $282.8483 per share, executed in multiple trades within a $280.95–$283.90 price range, following an option exercise at $101.64 per share.

Was Michael J. Farrell’s ResMed (RMD) stock sale under a Rule 10b5-1 plan?

Yes, the sale was conducted under a Rule 10b5-1 plan adopted on October 31, 2024. Such plans pre-arrange trade timing and size, providing a structured framework for insider sales independent of subsequent market-sensitive information.

What were the key terms of the ResMed (RMD) stock options Michael J. Farrell exercised?

The options covered 8,009 shares at an exercise price of $101.64 per share, first became exercisable on November 11, 2019, vested one-third per year, and were scheduled to expire on November 14, 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farrell Michael J.

(Last) (First) (Middle)

RESMED INC.

9001 SPECTRUM CENTER BLVD

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock	10/07/2025		M(1)		8,009	A	$101.64	475,801	D
ResMed Common Stock	10/07/2025		S(1)		8,009	D	$282.8483(2)	467,792	D
ResMed Common Stock								2,090	I	Lisette and Michael Farrell Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
ResMed Common Stock Options	$101.64	10/07/2025		M			8,009	11/11/2019(3)	11/14/2025	ResMed Common Stock	8,009	$0	8,011	D

Explanation of Responses:

1. The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.

2. This transaction was executed in multiple trades at prices ranging from $280.95 - $283.90. The price reported above reflects the weighted average sale price.

3. Represents date options first become exercisable. Options vest 1/3 per year.

	Michael J. Farrell, Chief Executive Officer	10/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.